Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050731 | 0.79 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL3516320 | 0.79 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4702959 | 0.79 | SLC6A7 (0.54) | CHRNA7HTR3A | |
| SCHEMBL6370221 | 0.79 | CHRNA7 (0.43) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7479934 | 0.78 | L3MBTL1 (0.57) | L3MBTL1CHRNA7EPHX2CHRNA3CHRNB2 | |
| SCHEMBL4700028 | 0.78 | GHSR (0.46) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4700217 | 0.77 | KDM4E (0.56) | CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL4701391 | 0.77 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4700995 | 0.77 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4030570 | 0.76 | CHRNA7 (0.60) | L3MBTL1CHRNA7HTR3ACHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | CHRND, CHRNE, CHRM2 | L3MBTL1 3727/4885CHRNA7 17/4885HTR3A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.